Title: Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
Journal: Investigational new drugs 20150601
Title: Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20140815
Title: MEK and the inhibitors: from bench to bedside.
Journal: Journal of hematology & oncology 20130101
Title: Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120901
Title: Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.
Journal: Bioorganic & medicinal chemistry letters 20110315
Title: Hypertension in pregnancy: an invitational symposium.
Journal: The Journal of reproductive medicine 19751101
Title: Lee L, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker. Clin Cancer Res. 2009 Dec 1;15(23):7368-74.
Title: Tegnebratt T, et al. Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F FDG-PET imaging combined with proteomic approaches. EJNMMI Res. 2014 Dec;4(1):34.
